Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead's accounting chief hits the exit—Chutes & Ladders
Gilead’s accounting chief hits the exit. Geron chief says goodbye. ITM preps for launch with leadership shake-up.
Darren Incorvaia
,
Zoey Becker
Mar 14, 2025 8:30am
Gilead loses interest in Arcus' rival to Merck's Welireg
Feb 18, 2025 8:19am
Gilead roars into JPM25 with $250M upfront deal for Leo
Jan 11, 2025 5:30pm
Galapagos splits in 2, laying off 40% of staff
Jan 8, 2025 4:49am
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Dec 19, 2024 11:54am
AI-powered Terray is teaming up with Gilead in a fresh R&D pact
Dec 17, 2024 8:00am
